Get started
Author

Shigeo Shimose

Observed names: S. Shimose, S., Shimose, SHIGEO SHIMOSE, Shigeo Simose, Shimose Shigeo, Shimose, S., 下瀬茂男
Institution: Kurume University
ORCID: 0000-0003-2068-8386
Observed ORCID: 0000-0003-2068-8386
OpenAlex ID: A5037691579
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population
2022 · Andrea Casadei-Gardini, Margherita Rimini, et al. · European Journal of Cancer · 131
PDF
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity
2023 · Hideki Iwamoto, Shigeo Shimose, et al. · Clinical and Molecular Hepatology · 88
PDF
Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study
2020 · Shigeo Shimose, Hideki Iwamoto, et al. · Cancers · 78
PDF
Clinical characteristics and prognostic factors for advanced hepatocellular carcinoma with extrahepatic metastasis
2014 · HAJIME AINO, SHUJI SUMIE, et al. · Molecular and Clinical Oncology · 76
PDF
Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse Events
2020 · Hideki Iwamoto, Hiroyuki Suzuki, et al. · Cancers · 70
PDF
Effects of in‐hospital exercise on liver function, physical ability, and muscle mass during treatment of hepatoma in patients with chronic liver disease
2016 · Shunji Koya, Takumi Kawaguchi, et al. · Hepatology Research · 70
PDF
Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study
2015 · Masahito Nakano, Masatoshi Tanaka, et al. · Cancer Medicine · 66
PDF
Lenvatinib prolongs the progression‑free survival time of patients with intermediate‑stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis
2020 · Shigeo Shimose, Takumi Kawaguchi, et al. · Oncology Letters · 63
PDF
Lenvatinib versus sorafenib in first‐line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis
2021 · Andrea Casadei‐Gardini, Mario Scartozzi, et al. · Liver International · 61
Effects of in‐hospital exercise on sarcopenia in hepatoma patients who underwent transcatheter arterial chemoembolization
2018 · Shunji Koya, Takumi Kawaguchi, et al. · Journal of Gastroenterology and Hepatology · 60
PDF
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients
2023 · Mara Persano, Margherita Rimini, et al. · European Journal of Cancer · 58
PDF
Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
2021 · Hideki Iwamoto, Shigeo Shimose, et al. · Cancers · 58
PDF
Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study
2021 · Shigeo Shimose, Hideki Iwamoto, et al. · Cancers · 57
PDF
Diffusion-weighted magnetic resonance imaging predicts malignant potential in small hepatocellular carcinoma
2016 · Shusuke Okamura, Shuji Sumie, et al. · Digestive and Liver Disease · 49
Prognostic impact of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma: Comparison with TACE alone using decision‐tree analysis after propensity score matching
2019 · Shigeo Shimose, Masatoshi Tanaka, et al. · Hepatology Research · 48
PDF
Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study
2021 · Margherita Rimini, Shigeo Shimose, et al. · Hepatology Research · 46
PDF
Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study
2020 · Shigeo Shimose, Takumi Kawaguchi, et al. · Nutrients · 46
PDF
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients
2023 · Margherita Rimini, Mara Persano, et al. · Journal of Cancer Research and Clinical Oncology · 42
PDF
Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
2022 · Takashi Niizeki, Takayuki Tokunaga, et al. · Targeted Oncology · 41
PDF
Radiofrequency ablation combined with transarterial chemoembolization for intermediate hepatocellular carcinoma
2013 · Masatoshi Tanaka, Eiji Ando, et al. · Hepatology Research · 41
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study
2022 · Andrea Casadei-Gardini, Margherita Rimini, et al. · Liver Cancer · 39
PDF
Spontaneous regression of hepatocellular carcinoma with reduction in angiogenesis‐related cytokines after treatment with sodium‐glucose cotransporter 2 inhibitor in a cirrhotic patient with diabetes mellitus
2018 · Takumi Kawaguchi, Dan Nakano, et al. · Hepatology Research · 37
The impact of curative conversion therapy aimed at a cancer‐free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
2023 · Shigeo Shimose, Hideki Iwamoto, et al. · Cancer Medicine · 36
PDF
The systemic inflammatory response as a prognostic factor for advanced hepatocellular carcinoma with extrahepatic metastasis
2016 · HAJIME AINO, SHUJI SUMIE, et al. · Molecular and Clinical Oncology · 34
PDF
Clinical effects and safety of intra‑arterial infusion therapy of cisplatin suspension in lipiodol combined with 5‑fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra‑hepatic spread: A prospective cohort study
2017 · Masahito Nakano, Takashi Niizeki, et al. · Molecular and Clinical Oncology · 33
PDF
Works count: 153
Citation count: 2,400
H-index: 29
I10-index: 70
Year
Topic
Type